Week in Review: China Pharma Deals Top $1.5 Billion for Week

Deals and Financings Tianjin Tasly Pharma is in talks to IPO its biopharma division in Hong Kong with the goal of raising $1 billion; Hua Medicine of Shanghai is planning a $400 million IPO in Hong Kong to fund the company's lead drug, a novel oral diabetes 2 treatment; Shanghai 's JW Therapeutics, a JV formed by Juno Therapeutics and WuXi AppTec, closed a $90 million Series A financing to develop immunotherapies; 23Mofang of Chengdu raised $15.8 million in venture financing to develop its saliva-based genetic test for individuals; Oxford Vacmedix, a UK-Changzhou biopharma, closed a $12.5 million Series A funding from Asian investors to develop therapeutic cancer vaccines; MicuRx Pharma, a US-China anti-infective company, will receive up to $5.2 million from a global partnership, CARB-X; Adagene, a Suzhou antibody company, formed a strategic collaboration with WuXi Biologics for process development and manufacturing of Adagene products; Trials and Approvals TaiMed Biologics of Taiwan received US marketing approval for a novel HIV-1 treatment aimed at multi-drug-resistant patients; Hutchison China MediTech (Chi-Med) has started a China Phase Ib/II proof-of-concept study of its EFGR inhibitor in glioblastoma patients. Stock Symbols: (SHA: 600535) (HK: 2269) (TWO: 4147) (AIM/NSDQ: HCM) Share this with colleagues: // //